Life Sciences & MedTech Investment Diligence
Decision quality, from someone who has operated the decisions.
SVI helps PE and VC investors determine whether a life sciences or medtech investment thesis is supported by the evidence, economics, and execution required to create value. Every engagement is led by Bob Basore, whose senior executive experience spans strategy, R&D, corporate development and M&A, commercialization, market access, and P&L leadership across pharma, biotech, diagnostics, medical devices, and radiopharmaceuticals.
Particular depth in oncology, radiopharma/theranostics, diagnostics/IVD/NGS, and medtech.
Pressure-test the thesisOne investment thesis. One integrated point of view.
Clinical, regulatory, reimbursement, commercial, manufacturing, and organizational findings are not separate answers. They matter when they change the investment decision. SVI integrates the material findings into a single decision view so the investment team is not left to reconcile disconnected workstreams.
The same asset is not worth the same in every owner's hands.
Value depends not only on the asset, but also on the capabilities, capital, operating model, and decisions required to develop and commercialize it. SVI brings those realities into the investment case, especially where reimbursement, site economics, supply, or organizational capability can determine whether the forecast is actually achievable.
See the questions that can change the decision →Senior judgment without the handoff.
Bob Basore scopes and leads every engagement and owns the conclusion. When a decision requires deeper regulatory, clinical, reimbursement, HEOR, manufacturing, or primary-research expertise, SVI adds senior specialists for the specific question. Their work is integrated into one accountable view, not delivered as a collection of separate expert opinions.
PE / Growth Equity
Revenue quality, reimbursement and site economics, scalability, operational constraints, management capability, integration risk, and value capture.
VC / Strategic Investors
Technical and clinical evidence, development path, capital needs, milestone risk, market access, organizational capability, and risk-adjusted value.
Ways to engage
Explore the investment questions →Red-Flag Diligence / IC Read
Focused review of the assumptions most capable of changing the investment decision, with material risks, evidence gaps, downside implications, and the questions that still need to be resolved.
Integrated Investment Diligence
A deeper assessment across the scientific, clinical, regulatory, commercial, reimbursement, operational, and organizational dimensions relevant to the asset, integrated back to the investment thesis.
Value-Capture Blueprint
For operating or post-close situations, translate the investment thesis into the critical milestones, operating priorities, resources, and risks that determine whether modeled value is realized.
$10B+
Acquisition and portfolio activity
$1.2B
P&L responsibility
90+
Cross-functional oncology leadership
25+ years
Healthcare operating and executive experience